We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Genospectra Announces the Acquisition of Panomics

Genospectra Announces the Acquisition of Panomics

Genospectra Announces the Acquisition of Panomics

Genospectra Announces the Acquisition of Panomics

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genospectra Announces the Acquisition of Panomics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genospectra, Inc. has announced that it is merging with Panomics, Inc. Commenting on the merger, Dr. Frank Witney, Genospectra's CEO said, "Genospectra and Panomics have long discussed the remarkable synergy between our two businesses."

"We are impressed with the way that Panomics has quickly established a broad portfolio of innovative products for proteomics analysis and live-cell assays."

"We are convinced that when united with our PQB initiative, the combined entity will be well positioned for rapid growth since it will serve a wide range of customers in both academic and for-profit end markets."

By combining Panomics portfolio with Genospectra's products and technologies for Parallel Quantitative Biology, the new company will provide an integrated pipeline of products in the functional biology and drug discovery space.

The mission of the combined entity is to provide PQB products for basic life science research and critical applications such as cell signaling, RNAi-mediated gene silencing and high performance assays, clinical biomarker discovery and predictive toxicology.

With plans to launch a series of innovative products to study FFPE and blood biomarkers, protein-protein interactions, cell signaling and gene silencing, the new company has already established targeted goals.

Dr. Jason Li, former CEO of Panomics added, "We are excited to combine our efforts to drive functional biology programs with products that extend from cellular delivery and gene modulation to gene and protein expression, and ultimately through innovative live cell assays."

Ron Hahn of Battelle Ventures, Genospectra board member, and lead investor of Genospectra's Series C financing said, "This merger makes excellent sense for Genospectra's and Panomics' employees, customers and investors."

"By leveraging the strengths of two synergistic portfolios in complementary markets, it enables the combined company to grow rapidly and take its place among world-class life science reagents companies."

The companies will be merged under the name Panomics, with Dr. Witney of Genospectra as the new company's CEO and Dr. Li, founder and former CEO of Panomics, in the role of the new company's Chief Operating Officer.

In conjunction with the acquisition, Genospectra closed a $12.2 Million financing, with Sigma-Aldrich joining as a new strategic investor and partner, and certain existing investors and affiliates of both companies also participating.

A key strategic goal of the Sigma-Aldrich relationship is to help drive the development of the next generation of live cell biosensors and cell based assays.

George Lee of Amkey Ventures joined the Genospectra Board of Directors, which will become the new company's board. Following integration, the new Panomics will be headquartered at Genospectra's existing facilities in Fremont, California.